Trial Profile
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Nov 2019 Status changed from active, no longer recruiting to discontinued.
- 03 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Jan 2017 Status changed from not yet recruiting to recruiting.